Results 81 to 90 of about 50,069 (258)

Medical cannabis - the Canadian perspective.

Journal of pain research, 2016
Cannabis has been widely used as a medicinal agent in Eastern medicine with earliest evidence in ancient Chinese practice dating back to 2700 BC. Over time, the use of medical cannabis has been increasingly adopted by Western medicine and is thus a rapidly emerging field that all pain physicians need to be aware of. Several randomized controlled trials
Ko, Gordon D, Bober, Sara L, Mindra, Sean, Moreau, Jason M   +3 more
openaire   +2 more sources

Drug Use After Emergency Department‐Initiated Injectable Buprenorphine: A Secondary Analysis of the ED‐INNOVATION Ancillary Safety and Feasibility Trial

Academic Emergency Medicine, EarlyView.
ABSTRACT Study Objective To characterize opioid and nonopioid drug use in the week following emergency department (ED)‐initiated extended‐release buprenorphine (XR‐BUP) treatment using both self‐reported data and urine drug screens (UDS). Methods This study uses data collected during a nonrandomized clinical trial of patients with untreated opioid use ...
Ethan Cowan, Gail D'Onofrio, Jeanmarie Perrone, Erik Anderson, James Dziura, Kathryn Hawk, Andrew Herring, Ryan McCormack, Manali Phadke, Elizabeth A. Samuels, David A. Fiellin   +10 more
wiley   +1 more source

Daily or near‐daily cannabis and alcohol use by adults in the United States: A comparison across age groups

Addiction, Volume 120, Issue 4, Page 779-782, April 2025.
Abstract Background and aims Patterns of daily or near‐daily (DND) use of alcohol and cannabis among adults in the United States have been changing. The current study measured how these shifts have occurred across developmental periods of adulthood. Design, Setting, and Participants U.S.
Megan E. Patrick
wiley   +1 more source

Psychedelic‐assisted treatment for substance use disorder: A narrative systematic review

Addiction, EarlyView.
Abstract Background and aims This is the first systematic review of the extant literature on all major psychedelic‐assisted treatment for alcohol use disorder (AUD), tobacco use disorder (TUD) and other substance use disorders (SUD). We aimed to summarise the evidence for efficacy of psychedelic‐assisted treatment for AUD, TUD, and SUD; to evaluate its
Theodore Piper, Francesca Small, Sam Brown, Michael Kelleher, Luke Mitcheson, James Rucker, Allan H. Young, John Marsden   +7 more
wiley   +1 more source

Association of fully branded, standardized packaging and limited flavor and brand descriptors of e‐liquids with interest in trying products among youths in Great Britain

Addiction, Volume 120, Issue 4, Page 620-628, April 2025.
Abstract Background and aims Many vaping products feature bright colors and novel brand names and flavor descriptors, which may appeal to youth. We measured the strength of the associations between e‐liquid packaging design (branded, white standardized or white standardized limiting brand and flavor descriptors) and perceived peer interest in trying ...
Eve Taylor, Erikas Simonavičius, Matilda Nottage, Ann McNeill, Deborah Arnott, Hazel Cheeseman, David Hammond, Jessica Reid, Pete Driezen, Kimberly D'Mello, Katherine East   +10 more
wiley   +1 more source

How older Canadians access medical cannabis and information about it: A descriptive survey

Cogent Gerontology
To understand older adults’ perceptions regarding access to medical cannabis and information related to it. We employed cross-sectional survey design to recruit Canadians (≥60 years) who consume cannabis for health purpose(s).
Shovana Shrestha, Sherry Dahlke, Jeffrey I. Butler, Rashmi Devkota, Joanna Law, Kathleen F. Hunter, Madeline Toubiana, Maya R. Kalogirou, Melissa Scheuerman, Matthew Pietrosanu   +9 more
doaj   +1 more source

Cannabis products: medical use

Revista da Associação Médica Brasileira, 2023
César Eduardo Fernandes, José Eduardo Lutaif Dolci, Leonardo Sobral Navarro, Marcelo Allevato, Clóvis Francisco Constantino, Rodrigo Pastor Alves Pereira, Carlos Roberto de Mello Rieder, Flávia Torino, Wanderley Marques Bernardo, Antônio Geraldo da Silva   +9 more
openaire   +3 more sources

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

Addiction, EarlyView.
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsistent. Depression following alcohol detoxification significantly increases the risk of relapse. This pilot study aimed to evaluate the feasibility, acceptability, and preliminary efficacy of psilocybin‐assisted
Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul Rochefort, Thibault Mura, Felix Sergent   +7 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

‘I'd rather have worse gums than worse lungs’: Young people's views of nicotine pouches in the UK

Addiction, EarlyView.
Abstract Background and aims Nicotine pouches entered the UK market in 2019. Although research has shown that young people's prevalence of use has been low, it has been reported to be increasing and a cause for concern. This paper reports the findings of the first qualitative study in the UK to explore the views of 14–16 year olds' knowledge, awareness
Andy MacGregor, Jessica Shields, Asiya Hamid, Eleanor Holman, Hannah Biggs, Sarah Minty, Jamie Pearce, Allison Ford   +7 more
wiley   +1 more source